175 related articles for article (PubMed ID: 29587865)
41. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
42. Cell death-based treatment of lung adenocarcinoma.
Denisenko TV; Budkevich IN; Zhivotovsky B
Cell Death Dis; 2018 Jan; 9(2):117. PubMed ID: 29371589
[TBL] [Abstract][Full Text] [Related]
43. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
44. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
45. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
46. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
47. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
Kermanshahi TR; Jayachandran P; Chang DT; Pai R
Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
[TBL] [Abstract][Full Text] [Related]
48. Pediatric lung adenocarcinoma presenting with brain metastasis: a case report.
De Martino L; Errico ME; Ruotolo S; Cascone D; Chiaravalli S; Collini P; Ferrari A; Muto P; Cinalli G; Quaglietta L
J Med Case Rep; 2018 Sep; 12(1):243. PubMed ID: 30172261
[TBL] [Abstract][Full Text] [Related]
49. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
Ikeda S; Fujimori M; Shibata S; Okajima M; Ishizaki Y; Kurihara T; Miyata Y; Iseki M; Shimizu Y; Tokumoto N; Ozaki S; Asahara T
BMC Cancer; 2006 Feb; 6():31. PubMed ID: 16451736
[TBL] [Abstract][Full Text] [Related]
50. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
51. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
Li W; Qiu T; Ling Y; Gao S; Ying J
Mol Oncol; 2018 May; 12(5):677-689. PubMed ID: 29518290
[TBL] [Abstract][Full Text] [Related]
52. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
[TBL] [Abstract][Full Text] [Related]
53. High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis.
Watson R; Liu TC; Ruzinova MB
Hum Pathol; 2016 Oct; 56():163-70. PubMed ID: 27346571
[TBL] [Abstract][Full Text] [Related]
54. Pulmonary enteric adenocarcinoma indistinguishable morphologically and immunohistologically from metastatic colorectal carcinoma.
László T; Lacza A; Tóth D; Molnár TF; Kálmán E
Histopathology; 2014 Aug; 65(2):283-7. PubMed ID: 24571601
[No Abstract] [Full Text] [Related]
55. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
56. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.
Chen Y; Yang Y; Ma L; Zhu H; Feng T; Jiang S; Wei Y; Wang T; Sun X
Eur J Radiol; 2019 Mar; 112():44-51. PubMed ID: 30777218
[TBL] [Abstract][Full Text] [Related]
57. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
58. Using DNA sequencing data to quantify T cell fraction and therapy response.
Bentham R; Litchfield K; Watkins TBK; Lim EL; Rosenthal R; Martínez-Ruiz C; Hiley CT; Bakir MA; Salgado R; Moore DA; Jamal-Hanjani M; ; Swanton C; McGranahan N
Nature; 2021 Sep; 597(7877):555-560. PubMed ID: 34497419
[TBL] [Abstract][Full Text] [Related]
59. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y
Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinoma.
Jin L; Liu Y; Wang X; Qi X
Biotech Histochem; 2018; 93(5):364-372. PubMed ID: 29956575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
